Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature

The tumor suppressor p53, encoded by the TP53 gene, is mutated or nullified in nearly 50% of human cancers. It has long been debated whether TP53 mutations can be utilized as a biomarker to predict clinical outcomes of cancer patients. In this study, we applied computational methods to calculate p53...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaafsma, Evelien, Takacs, Eric M., Kaur, Sandeep, Cheng, Chao, Kurokawa, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789768/
https://www.ncbi.nlm.nih.gov/pubmed/35079034
http://dx.doi.org/10.1038/s41598-022-05243-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789768/
https://www.ncbi.nlm.nih.gov/pubmed/35079034
http://dx.doi.org/10.1038/s41598-022-05243-6

Ejemplares similares